Arbutus Biopharma Reports Third Quarter 2026 Financial Results and Corporate Update
Arbutus Biopharma reported its third quarter 2026 financial results, highlighting a net income of $59.1 million and the lifting of a U.S. FDA clinical hold on its oral PD-L1 inhibitor, AB-101.